Ireland - English - HPRA (Health Products Regulatory Authority)

yamanouchi pharma ltd - unknown

Ireland - English - HPRA (Health Products Regulatory Authority)

yamanouchi pharma ltd - cream

Ireland - English - HPRA (Health Products Regulatory Authority)

yamanouchi pharma ltd -

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: sodium hydroxide; water for injections; lactic acid; sorbitol - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: sorbitol; lactic acid; water for injections; sodium hydroxide - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - simvastatin, quantity: 80 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; butylated hydroxyanisole; microcrystalline cellulose; magnesium stearate; lactose monohydrate; ascorbic acid; citric acid monohydrate; titanium dioxide; hypromellose; purified talc; iron oxide red; hyetellose - simvastatin is indicated as an adjunct to diet for treatment of hypercholesterolaemia. prior to initiating therapy with simvastatin, secondary causes of hypercholesterolaemia (eg poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. simvastatin is indicated in patients at high risk of chd (coronary heart disease) (with or without hypercholesterolaemia), including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - simvastatin, quantity: 40 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; lactose monohydrate; butylated hydroxyanisole; citric acid monohydrate; pregelatinised maize starch; ascorbic acid; titanium dioxide; hypromellose; purified talc; iron oxide red; hyetellose - simvastatin is indicated as an adjunct to diet for treatment of hypercholesterolaemia. prior to initiating therapy with simvastatin, secondary causes of hypercholesterolaemia (eg poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. simvastatin is indicated in patients at high risk of chd (coronary heart disease) (with or without hypercholesterolaemia), including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - simvastatin, quantity: 20 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; pregelatinised maize starch; ascorbic acid; butylated hydroxyanisole; citric acid monohydrate; titanium dioxide; hypromellose; hyprolose; purified talc; iron oxide red; iron oxide yellow - simvastatin is indicated as an adjunct to diet for treatment of hypercholesterolaemia. prior to initiating therapy with simvastatin, secondary causes of hypercholesterolaemia (eg poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. simvastatin is indicated in patients at high risk of chd (coronary heart disease) (with or without hypercholesterolaemia), including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - simvastatin, quantity: 10 mg - tablet, film coated - excipient ingredients: ascorbic acid; lactose monohydrate; citric acid monohydrate; microcrystalline cellulose; butylated hydroxyanisole; magnesium stearate; pregelatinised maize starch; titanium dioxide; hyprolose; hypromellose; purified talc; iron oxide red; iron oxide yellow; iron oxide black - simvastatin is indicated as an adjunct to diet for treatment of hypercholesterolaemia. prior to initiating therapy with simvastatin, secondary causes of hypercholesterolaemia (eg poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. simvastatin is indicated in patients at high risk of chd (coronary heart disease) (with or without hypercholesterolaemia), including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - simvastatin, quantity: 80 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; ascorbic acid; pregelatinised maize starch; citric acid monohydrate; microcrystalline cellulose; butylated hydroxyanisole; titanium dioxide; hypromellose; purified talc; iron oxide red; hyetellose - simvastatin is indicated as an adjunct to diet for treatment of hypercholesterolaemia. prior to initiating therapy with simvastatin, secondary causes of hypercholesterolaemia (eg poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. simvastatin is indicated in patients at high risk of chd (coronary heart disease) (with or without hypercholesterolaemia), including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.